Business Wire

Taiwan: Rising Importance of Proton Therapy and a Fortress for Cancer Treatment

Share

There is no place like Taiwan where medical services are readily accessible with quality and efficiency, attracting nearly 500,000 patients worldwide annually and attention from dominant medical devices suppliers.

Cancer treatment is one of medical specialties that Taiwan gains recognition in Asia. The focal point now goes to proton therapy, which is proven to be a painless way to deliver radiation dose in targeted tumours precisely and maintains side effects happening in the minimum level.

Proton therapy key players race for Asia markets

Despite proton therapy indicating a promising alternative for cancer treatments, it is far from close to a mainstream service that can be found in medical institutes. As per PTCOG statistics, there are 82 medical institutes to date having the therapy on offer, with one in operation and 9 to go in Taiwan- the highest density as opposed to the rest of the world. Chang Gung Memorial Hospital launched the service in 2015, followed closely by its peers including Taipei Medical University Hospital, China Medical University Hospital, Taipei Veterans General Hospital, National Taiwan University Hospital and 5 more known domestically and regionally, aiming at increasing demands by patients in ASEAN nations.

Multinational medical device tycoons, too, leap at opportunities they see in Taiwan by forming allies to medical centres, namely IBA, Varian, Hitachi and SHI Group. Their presence suggests that Taiwan is well positioned with its medical expertise and geographic location for being a demo site where business would develop from, it also approves Taiwan’s capacity for driving innovation and application of cancer treatment.

Taiwan excels at treating cancers in head, neck and breast areas, and tumours found in children

Proton therapy combining with other treatments is found useful for lung cancer and tumours in head and neck areas. Taiwan-based medical institutes have been propelling positive results through clinical cases and research, noting that breast cancer and cancers developed in children can be a critical addition to strengthen Taiwan’s strategic foothold in Asia, together with engineering and science specialists involved in course of treatment.

Multinational manufacturers of radiation therapy (including proton) equipment and their hospital partners will feature live demonstration and techniques behind advanced cancer treatment on 5-8 December 2019, at the Healthcare+ Expo Taiwan .

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Healthcare+ Expo Taiwan
Silvia Fan
+886 2 2655 7888 Ext.649
silvia@rbmp.org.tw

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kao Releases the Kao Integrated Report 202513.6.2025 05:00:00 EEST | Press release

Kao Corporation (TOKYO:4452) has published the Kao Integrated Report 2025 on its website, offering shareholders, investors, and all stakeholders with a comprehensive overview of the company’s initiatives and strategic direction. Kao Integrated Report 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609991718/en/ The cover visual represents our “moonshot.” It embodies our commitment to achieving the ambitious goal of a sustainable society for future generations. To achieve its Mid-term Plan “K27,” Kao aims to become a unique presence indispensable to someone in the world and is advancing its Global Sharp Top strategy. In FY2024, Kao exceeded its targets by strengthening Return on Invested Capital (ROIC) management and strategically investing to build stronger, more robust businesses. This report offers an in-depth look at Kao’s progress under K27, highlighting how Kao’s dedicated employees—through the Global Sharp Top s

Phase 3 Data for Incyte’s Retifanlimab (Zynyz ® ) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 01:45:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer (SCAC) who have not been previously treated with systemic chemotherapy, were published in The Lancet.1 “The publication of the POD1UM-303/InterAACT 2 trial in The Lancet is a testament to the strength of the data generated for retifanlimab in patients with inoperable locally recurrent or metastatic SCAC, a disease which until recently had seen limited innovation for decades,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “SCAC can be a devastating disease, and patients often have a poor prognosis. These data supported the U.S. Food and Drug Administration (FDA) approval of Zynyz® (retifanl

Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 22:30:00 EEST | Press release

Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal, but a core driver of innovation. Key milestones include a near-complete transition to natural refrigerants

Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 21:45:00 EEST | Press release

Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of European enterprises, providing a framework for high performance in even the most complex, secure environments. “With about 6 million developers across Europe, users deserve infrastructure that meets them where they are,” said Varun Mohan, CEO of Windsurf. “The demand for secure AI-powered development is undeniable and by launching this GPU cluster, we aim to b

Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 20:00:00 EEST | Press release

Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization journey, allowing developers to focus on building engaging games, not commerce infrastructure. This SDK connects three

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye